Ludwig Kappos
Ludwig Kappos
University Hospital Basel
Verified email at uhbs.ch
TitleCited byYear
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ...
Annals of neurology 69 (2), 292-302, 2011
72582011
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
55302005
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ...
New England Journal of Medicine 354 (9), 899-910, 2006
30212006
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
L Kappos, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi, ...
New England Journal of Medicine 362 (5), 387-401, 2010
23682010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ...
New England Journal of Medicine 362 (5), 402-415, 2010
21022010
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
14192014
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ...
New England Journal of Medicine 367 (12), 1098-1107, 2012
12702012
Oral fingolimod (FTY720) for relapsing multiple sclerosis
L Kappos, J Antel, G Comi, X Montalban, P O'Connor, CH Polman, T Haas, ...
New England Journal of Medicine 355 (11), 1124-1140, 2006
11002006
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ...
The Lancet Neurology 17 (2), 162-173, 2018
9662018
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ...
Neurology 67 (7), 1242-1249, 2006
8612006
Randomized trial of oral teriflunomide for relapsing multiple sclerosis
P O'Connor, JS Wolinsky, C Confavreux, G Comi, L Kappos, TP Olsson, ...
New England Journal of Medicine 365 (14), 1293-1303, 2011
8032011
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
PL De Jager, X Jia, J Wang, PIW De Bakker, L Ottoboni, NT Aggarwal, ...
Nature genetics 41 (7), 776, 2009
7802009
Differential diagnosis of suspected multiple sclerosis: a consensus approach
DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ...
Multiple Sclerosis Journal 14 (9), 1157-1174, 2008
6732008
Ocrelizumab versus placebo in primary progressive multiple sclerosis
X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ...
New England Journal of Medicine 376 (3), 209-220, 2017
6592017
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the …
L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ...
The Lancet 370 (9585), 389-397, 2007
6372007
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or, F Barkhof, M Yin, ...
The Lancet 378 (9805), 1779-1787, 2011
6342011
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
L Kappos
The Lancet 352 (9139), 1491-1497, 1998
6201998
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ...
New England Journal of Medicine 376 (3), 221-234, 2017
5622017
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled …
L Kappos, G Comi, H Panitch, J Oger, J Antel, P Conlon, L Steinman, ...
Nature medicine 6 (10), 1176-1182, 2000
5302000
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
PA Calabresi, EW Radue, D Goodin, D Jeffery, KW Rammohan, AT Reder, ...
The Lancet Neurology 13 (6), 545-556, 2014
5092014
The system can't perform the operation now. Try again later.
Articles 1–20